Humacyte (HUMA) Operating Leases (2020 - 2023)

Humacyte (HUMA) has reported Operating Leases for 4 consecutive years, with $632000.0 the latest figure, recorded in Q4 2023.

• On a quarterly basis, Operating Leases fell 9.71% year-over-year to $632000.0 in Q4 2023; TTM through Dec 2023 was $632000.0, a 9.71% decrease from a year earlier, with the FY2023 full-year figure at $632000.0, down 9.71% from the prior year.
• Operating Leases was $632000.0 for Q4 2023 at Humacyte, up from $620000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $800000.0 in Q4 2020 and troughed at $620000.0 in Q1 2023.
• A 4-year average of $679777.8 and a median of $670000.0 in 2022 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases decreased 12.5% in 2021 and changed 0.0% in 2022, its largest moves.
• Over 4 years, Operating Leases stood at $800000.0 in 2020, then declined by 12.5% to $700000.0 in 2021, then changed by 0.0% to $700000.0 in 2022, then retreated by 9.71% to $632000.0 in 2023.
• The last three Operating Leases figures came in at $632000.0 (Q4 2023), $620000.0 (Q1 2023), and $700000.0 (Q4 2022), per Business Quant data.